FDA Clears a New Stroke Drug, Flags a GLP-1 Eye Risk, and America Faces a Measles Reckoning
FDA approves a novel stroke drug and flags a rare GLP-1 eye risk; US measles cases hit a 35-year high as an elimination deadline looms.
By BINA Editorial
Three regulatory decisions and one slow-moving public-health crisis dominated health news this week. The FDA closed out a busy stretch by clearing a first-in-class stroke drug and updating warning labels for the most popular weight-loss medications on the market, while epidemiologists tracked an accelerating measles outbreak that could strip the United States of a status it has held for a quarter-century.
FDA Approves Sunharbo — the First Factor XIa Inhibitor for Stroke Prevention
On November 9, the FDA approved asundexian (brand name Sunharbo, Bayer) for secondary stroke prevention, making it the first Factor XIa inhibitor to reach US patients. The approval marks a meaningful shift in how physicians can approach clot risk after an ischemic stroke or high-risk transient ischemic attack.
Factor XIa sits upstream in the coagulation cascade and plays a larger role in pathological clot formation than in the normal hemostatic response that stops bleeding wounds. Drugs that block it aim to prevent recurrent strokes without adding the bleeding risk that has long complicated anticoagulant therapy — a tradeoff that has been difficult to escape with older agents like warfarin or even newer direct oral anticoagulants.
The approval rests on the Phase 3 OCEANIC-STROKE trial, which enrolled 12,327 adults with recent mild-to-moderate noncardioembolic ischemic stroke or high-risk TIA. Asundexian added on top of standard antiplatelet therapy reduced ischemic stroke risk by 26 percent over a median 14.2 months of follow-up. Diarrhea was the most common adverse reaction reported. The drug is not approved for stroke prevention in atrial fibrillation, a distinction neurologists will need to communicate clearly.
Bayer said it expects US shipments to begin in mid-to-late November 2026. Regulators in Europe, Japan, and China — which approved the drug on October 26 — are conducting parallel reviews.
GLP-1 Drugs Get a New Warning: Rare Risk of Permanent Vision Loss
Also on November 9, the FDA updated labeling for the entire GLP-1 receptor agonist drug class — including Ozempic and Wegovy (semaglutide, Novo Nordisk), Zepbound and Mounjaro (tirzepatide, Eli Lilly), and roughly a dozen other injectable and oral agents — to warn of a rare risk of non-arteritic anterior ischemic optic neuropathy, or NAION.
NAION is caused by reduced blood flow to the optic nerve. It strikes suddenly and without pain, and in some patients the vision loss is permanent. Warning signs include abrupt one-eye vision loss, blurred or missing areas of sight, faded colors, and hazy spots in central vision. Patients experiencing these symptoms should contact a healthcare provider immediately.
The FDA estimates the incidence at roughly 6 per 100,000 GLP-1 users per year, compared with approximately 4 per 100,000 among people on a placebo or a different diabetes drug — a small absolute difference but a statistically meaningful signal the agency felt obligated to communicate. The review was triggered by a 2024 paper linking semaglutide to NAION cases in certain patients.
Patients who have already experienced NAION are advised to discuss with their doctor whether to continue GLP-1 therapy. The updated labeling does not recommend discontinuing treatment for most users; GLP-1 drugs carry well-established cardiovascular and metabolic benefits for large patient populations. The new warning is about informed consent and vigilance, not a recall or contraindication.
America Is Weeks from Losing Its Measles-Free Status
The United States has confirmed at least 5,182 measles cases so far in 2026 — the highest annual total in 35 years and more than double the 2,289 cases recorded throughout all of 2025. Cases have been reported in 45 states, and 11 deaths have been linked to outbreaks since early 2025.
The Pan American Health Organization has convened a November 2026 review to assess whether the US still meets the criteria for measles elimination, a designation it earned in 2000 after decades of vaccination campaigns. Canada lost its own elimination status in November 2025 after a comparable outbreak pattern. A Lancet analysis concluded earlier this year that it appears highly likely the US will follow.
CDC director Erica Schwartz has said the agency will continue working with states regardless of the official outcome, but losing the designation carries real consequences: it signals to the global health community that endemic transmission has resumed, it complicates outbreak response internationally, and it underscores the depth of the vaccination-confidence crisis that has been building in the US since 2019.
Public health officials have pointed to declining childhood vaccination rates — particularly in communities where MMR uptake has fallen below the 95 percent threshold needed for herd immunity — as the primary driver. Measles is one of the most contagious pathogens known; a single infected person can expose 12 to 18 others in an unvaccinated population. The PAHO review result is expected before the end of November.
Prostate Cancer Cases Are Surging — The ACS Wants Men Talking to Their Doctors Earlier
The American Cancer Society estimates 333,830 new prostate cancer cases and 36,320 deaths in the United States in 2026, reinforcing what oncologists have been warning about for several years: after a period of relative stability, incidence is climbing again, driven partly by an aging population and partly by the residual effect of earlier under-screening.
In a September awareness push, the ACS renewed its call for men to begin shared decision-making conversations about PSA screening at age 50 for average-risk individuals. Men at higher risk — including African American men, who are diagnosed at nearly twice the rate of white men and die from the disease at more than double the rate, and men with a first-degree relative diagnosed before age 65 — should have that conversation at age 40 to 45.
The ACS also highlighted the role of genetic counseling for men with a strong family history of cancer, as inherited mutations in genes like BRCA2 and PALB2 meaningfully increase prostate cancer risk and can inform both screening intensity and treatment decisions.
The rising case count is a signal that the healthcare system needs to close gaps in early detection, particularly for high-risk men who historically have had less access to regular preventive care. Prostate cancer, when caught early, is highly treatable; the challenge — and the message the ACS is trying to drive home — is making sure high-risk patients are in the room before symptoms appear.